logo-loader
viewMedexus Pharmaceuticals Inc

Medexus expects public reimbursement for its joint-disease drug to roll out 'almost immediately'

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive that price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH) in Canada are complete.

d’Entremont says the public reimbursement is expected to roll out in a few of the Canadian provinces almost immediately and over the coming months, and should help Medexus expand sales and market access.

Quick facts: Medexus Pharmaceuticals Inc

Price: 2.5 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $35.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

1 week ago

2 min read